Rational design of GPER-targeted warheads for LYTACs or AbTAC-drug conjugates (ATDCs) holds promise for degrading membrane-bound GPER, blocking downstream signaling, and enabling intracellular delivery of conjugated drugs in the treatment of ER+/HER2− advanced BC patients. The gene discussed is GPER1; the disease is breast cancer.